Ocular Therapeutix (OCUL) Current Deferred Revenue (2013 - 2026)
Ocular Therapeutix's quarterly Current Deferred Revenue came in at $14.0 million in Q1 2026, up 21775.0% year-on-year from N/an in Q1 2025, and little changed quarter-over-quarter from $14.0 million in Q4 2025.
Ocular Therapeutix has reported Current Deferred Revenue for 9 years, with the latest figure at $14.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 21775.0% year-over-year to $14.0 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (up 21775.0% YoY), and the FY2025 full-year result was $14.0 million, up 10837.5% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $14.0 million, roughly flat from $14.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $14.6 million in Q2 2023, with the low at $64000.0 in Q1 2025.
- Average Current Deferred Revenue over 5 years is $8.5 million, with a median of $14.0 million recorded in 2025.
- Year-over-year, Current Deferred Revenue tumbled 99.11% in 2024 and soared 21775.0% in 2026.
- Tracing OCUL's Current Deferred Revenue over 5 years: stood at $14.0 million in 2022, then climbed by 3.06% to $14.4 million in 2023, then plunged by 99.11% to $128000.0 in 2024, then soared by 10837.5% to $14.0 million in 2025, then changed by 0.0% to $14.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $14.0 million (Q1 2026), $14.0 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 14.00 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 14.27 Mn |
| Mar 31, 2024 | 263,000.00 |
| Dec 31, 2023 | 14.39 Mn |
| Sep 30, 2023 | 317,000.00 |
| Jun 30, 2023 | 14.65 Mn |
| Mar 31, 2023 | 463,000.00 |
| Dec 31, 2022 | 13.96 Mn |
| Sep 30, 2022 | 14.14 Mn |
| Jun 30, 2022 | 14.19 Mn |
| Mar 31, 2022 | 1.21 Mn |
| Dec 31, 2021 | 13.00 Mn |
| Dec 31, 2015 | 42,000.00 |
| Sep 30, 2015 | 83,000.00 |
| Jun 30, 2015 | 125,000.00 |
| Mar 31, 2015 | 250,000.00 |
| Dec 31, 2014 | 188,000.00 |
| Sep 30, 2014 | 250,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Dec 31, 2013 | 250,000.00 |